Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $390733.0 in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 48.7% year-over-year to $390733.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390733.0 (down 48.7% YoY) and the FY2025 annual result came in at $495113.0, down 48.62% from the prior year.
• Non-Current Deferred Tax Liability retreated to $390733.0 in Q1 2026 per NEUP's latest filing, from $425527.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $1.3 million in Q2 2022 and bottomed at $390733.0 in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $796530.5 (2024), against an average of $756589.6.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability slipped 9.19%; it then sank 49.52% in 2025.
• Tracing NEUP's Non-Current Deferred Tax Liability over 5 years: stood at $1.3 million in 2022, then declined by 14.12% to $1.1 million in 2023, then dropped by 23.81% to $842921.0 in 2024, then slumped by 49.52% to $425527.0 in 2025, then decreased by 8.18% to $390733.0 in 2026.
• Per Business Quant, the three latest NEUP Non-Current Deferred Tax Liability figures stand at $390733.0 (Q1 2026), $425527.0 (Q4 2025), and $460320.0 (Q3 2025).

Peer Comparison